1. Rapid achievement of low-density lipoprotein cholesterol goals within 1 month after acute coronary syndrome during combination therapy with rosuvastatin, ezetimibe and bempedoic acid: Initial experience from the LAI-REACT study.
- Author
-
Mahajan, Kunal, Puri, Raman, Duell, P. Barton, Dutta, Deep, Yadav, Rahul, Kumar, Surender, Sharma, Jai Bharat, Patel, Prashant, Dsouza, Savio, Gupta, Ashu, Khan, Aziz, and Wong, Nathan D.
- Subjects
COMBINATION drug therapy ,REPEATED measures design ,ANTILIPEMIC agents ,PATIENT safety ,PATIENTS ,SCIENTIFIC observation ,CLINICAL trials ,HOSPITAL admission & discharge ,LDL cholesterol ,GOAL (Psychology) ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,ACUTE coronary syndrome ,EZETIMIBE ,ROSUVASTATIN ,C-reactive protein ,TIME - Abstract
• LAI-REACT was a single center, proof-of-concept, observational study. • Triple combination REB regimen was evaluated in 128 patients with ACS. • Triple combination REB regimen was found to be highly efficacious, safe and affordable. • 59.6% of patients achieved LAI target LDL-C < 50 mg/dl within the first week. • The reductions in LDL-C levels were sustained through 6 weeks of follow-up. • REB regimen was associated with a significant reduction in hsCRP levels. Rapid reduction of low-density lipoprotein cholesterol (LDL-C) to target levels immediately following acute coronary syndrome (ACS) event is critical to prevent future events. High-dose statins alone often fail to achieve LDL-C goals. Proprotein convertase subtilisin/kexin type-9 inhibitors (PCSK9i) combined with high-dose statins improves LDL-C goal attainment, but is unaffordable for many patients in India and worldwide. In a real-world open-label study, we demonstrated in a cohort of 122 patients with ACS, concurrent triple therapy with rosuvastatin 40 mg/d, ezetimibe 10 mg/d, and bempedoic acid 180 mg/d (REB) started at the time of hospital admission was associated with 57.7%, 61.7%, 61.9% and 60.6% reductions in LDL-C from 115.6 mg/dl at baseline to 48.9 mg/dl at week 1, 44.3 mg/dl at week 2, 44.1 mg/dl at week 4, and 45.6 mg/dl at week 6, respectively (each p < 0.001 compared to baseline; p < 0.001 across repeated measures). REB provided significant reductions in LDL-C within as early as one week and enabled 76.3% and 92.2% of patients to achieve the Lipid Association of India and American College of Cardiology recommended LDL-C targets of <50 mg/dl and <70 mg/dl within 2-weeks, respectively, which were sustained at 4–6 weeks. REB was generally well tolerated. Our study demonstrates the capacity to rapidly achieve LDL-C goals after ACS with triple REB therapy, an affordable regimen in India. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF